

Authors	Title	Journal	Remarks	Status
1. A Haider, L Gooren, P Padungtod, F Saad	Beneficial effects of two years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and on C-reactive protein	Horm Molec Biol Clin Invest 1(1): 27-34 (2010)		Published
2. F Saad, A Haider, L Gooren	Predictive value of age, body mass index and increment of plasma testosterone on the effects of testosterone treatment in hypogonadal men	J Sex Med 7 (Suppl. 2): 52 (2010)	Presented at SLAMS	Published
3. F Saad, A Haider	Testosterone administration to elderly hypogonadal men improves the metabolic syndrome, C-reactive protein, and liver steatosis	J Sex Med 7 (Suppl. 2): 66 (2010)	Presented at SLAMS	Published
4. A Haider, L Gooren, P Padungtod, F Saad	Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate	Exp Clin Endocrinol Diab 118(3): 167-171 (2010)		Published
5. F Saad, A Haider, P Padungtod, L Gooren	Reversal of symptoms of hypogonadism upon testosterone treatment are determined by achieved serum testosterone levels	J Asean Fed Endocr Soc 25, 1 (Suppl.): S81 (2010)	Presented at AFES	Published
6. F Saad, A Haider	Testosterone administration to elderly hypogonadal men improves the metabolic syndrome, C-reactive protein and liver steatosis	J Asean Fed Endocr Soc 25, 1 (Suppl.): S80-S81 (2010)	Presented at AFES	Published
7. F Saad, A Haider, A Yassin	Baseline testosterone levels or age as predictors of favourable effects of normalizing testosterone in men with the metabolic syndrome	J Sex Med 7 (Suppl. 2): 97-98 (2010)	Presented at APSSM	Published
8. F Saad, A Haider, W Kurtz, E Giltay, L Gooren	Administration of testosterone to elderly hypogonadal men with Crohn's disease improves their Crohn's disease activity index: a pilot study	Endocrine Abstracts 22: Abstract P198 (2010)	Presented at ECE	Published
9. A Yassin, A Haider, A Shamsodini, F Saad	Exogenous testosterone therapy and testicular volume – is there an alteration?	Eur J Sexol Sex Health 19 (Suppl. 1): S 99-S 100 (2010)	Presented at EFS	Published
10. A Haider, L Gooren, P Padungtod, F Saad	Beneficial effects of two years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and C-reactive protein	Abstract Book of the 3 rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension: 46A (2010)	Presented at CODHy	Published
11. F Saad, A Haider, W Kurtz, E Giltay, L Gooren	Administration of testosterone to elderly hypogonadal men with Crohn's disease improves the Crohn's Disease Activity Index: a pilot study	Abstract CD-ROM of 2010 Endocrine Society, Abstract P2-106	Presented at ENDO 2010	Published
12. A Yassin, F	Combination therapy for erectile dysfunction with testosterone and	Abstract CD-ROM of 2010 Endocrine Society,	Presented at ENDO	Published

Saad, A Haider	ildenafil in hypogonadal patients who failed to respond to testosterone treatment alone	Abstract P1-385	2010	Published
13. A Yassin, A Haider, F Saad	Hypogonadal patients receiving testosterone treatment for up to 5 years are not at higher risk of prostate cancer compared to age-matched controls	Abstract CD-ROM of 2010 Endocrine Society, Abstract P2-456	Presented at ENDO 2010	Published
14. F Saad, A Haider, A Yassin, L Gooren	Safety study of long-acting parenteral testosterone undecanoate over 42 months	Abstract CD-ROM of 2010 Endocrine Society, Abstract P2-450	Presented at ENDO 2010	Published
15. F Saad, A Haider, A Yassin, L Gooren	Upon continued testosterone administration to hypogonadal men, improvements in features of the metabolic syndrome are largest over the first 12-24 months but benefits are maintained	Abstract CD-ROM of 2010 Endocrine Society, Abstract P1-398	Presented at ENDO 2010	Published
16. F Saad, A Haider, A Yassin, L Gooren	Continued reduction of body weight and waist circumference over a 42 month period of testosterone administration to men with late onset hypogonadism	Obes Rev 11 (Suppl. 1): 272-273 (2010)	Presented at ICO 2010	Published
17. A Haider, P Padungtod, F Saad, L Gooren	A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months	Andrologia 42: 349-355 (2010)		Published
18. F Saad, A Haider, A Yassin, L Gooren	Testosterone administration reduces inflammation and may thus improve lower urinary tract symptoms	J Sex Med 7(Suppl. 4): 164-165 (2010)	Presented at ISSM	Published
19. F Saad, A Haider, A Yassin, L Gooren	Upon continued testosterone administration to hypogonadal men, improvements in features of the metabolic syndrome are largest over the first 12-24 months but benefits are maintained		Presented at 1 st HMBCI Symposium	Published
20. F Saad, A Haider, A Yassin, L Gooren	Safety study of long-acting parenteral testosterone undecanoate over 42 months		Presented at 1 st HMBCI Symposium	Published
21. A Yassin, A Haider, F Saad	Combination therapy for erectile dysfunction with testosterone and sildenafil in hypogonadal patients who failed to respond to testosterone treatment alone	Der Urologe 49 (Suppl. 1): 91 (2010)	Presented at DGU 2010	Published
22. A Haider, L Gooren, E Giltay, W Kurtz, F Saad	Administration of testosterone to elderly hypogonadal men with Crohn's disease improves their Crohn's Disease Activity Index: a pilot study	Horm Molec Biol Clin Invest 2(1): 287-292 (2010)		Published
23. A Haider, A Yassin, L Gooren	Safety study of long-acting parenteral testosterone undecanoate over 42 months	J Men's Health 7(3): 341 (2010)	Presented at WCMH 2010	Published

24. A Haider, A Yassin, L Gooren	Upon continued testosterone administration to hypogonadal men, improvements in features of the metabolic syndrome are largest over the first 12-24 months but benefits are maintained	J Men's Health 7(3): 341 (2010)	Presented at WCMH 2010	Published
25. F Saad, A Haider, A Yassin, L Gooren	Upon continued testosterone administration to hypogonadal men, improvements in features of the metabolic syndrome are largest over the first 12-24 months but benefits are maintained	Abstract Book of the 28 th Biennial Congress of the South African Urological Association: 24 (2010)	Presented at SAUA 2010	Published
26. F Saad, A Haider, A Yassin, L Gooren	Safety study of long-acting parenteral testosterone undecanoate over 42 months	Abstract Book of the 28 th Biennial Congress of the South African Urological Association: 24 (2010)	Presented at SAUA 2010	Published
27. L Gooren, F Saad, A Haider	Safety study of long-acting parenteral testosterone undecanoate over 42 months	J Endocrinol Metab 1(2) (Suppl.): 44 (2010)	Presented at AOCE 2010	Published